ANTITHROMBOTIC POTENTIAL AND HEMOSTATIC IMPACT OF MUMIYO (SHILAJIT) ON THE COAGULATION CASCADE

This study investigated how long-term administration of Mumiyo (Shilajit) at a dose of 100 mg/kg affects blood clotting in a canine model, monitoring five healthy adult dogs over a six-day timeline with blood tests taken at baseline, Day 3, Day 5, and Day 6. The findings showed that Mumiyo significantly reduced the body's ability to clot, which was proven by a clear, statistically significant lengthening of whole blood clotting time, plasma recalcification time, thrombin time, and heparin time. Furthermore, a steady increase in plasma tolerance to heparin indicated that the treatment made the blood much more sensitive to anticoagulant shifts. When looking at individual clotting factors, the data split over time: Factor II levels rose steadily throughout the study, while Factor V dropped temporarily before bouncing back to a significantly higher level. Interestingly, while total fibrinogen levels saw a moderate increase, the body's natural ability to break down clots (fibrinolytic activity) slowed down at the same time, meaning that once a clot did form, it took longer to degrade. Taken together, these results prove that Mumiyo pushes the entire circulatory system into a low-clotting (hypocoagulable) state, leading to the creation of fibrin networks that are structurally looser and less stable. These conclusions highlight the strong anti-clotting and clot-preventing potential of Mumiyo, highlighting the need for deeper scientific research to see how it can be safely used to treat blood disorders in clinical medicine